ClinicalTrials.gg

Program

senaparib

Also written as “IMP4297”, “IMP4297(20mg)” and “IMP4297(10mg)”.

Its studies are mostly in Breast Neoplasms · Ovarian Neoplasms · Small Cell Lung Carcinoma, led by Impact Therapeutics.

Furthest: phase 2, since Sep 3, 201912 company-led studies, 0 open or running

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Impact Therapeutics120 open or runningphase 2since Sep 3, 2019Jan 8, 2018none ahead

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Jan 8, 2018First studies: 2 phase 1 studies in Breast NeoplasmsFirst studyNCT03508011, NCT03507543
  2. Jul 29, 2019Phase 1 study in Solid TumorNCT04057729 · 16 enrolled · China
  3. Sep 3, 2019Phase 2 study in Ovarian NeoplasmsNCT04089189 · 93 enrolled · China
  4. Apr 15, 2020Phase 1 study in Solid TumorNCT04351165 · 18 enrolled · Australia
  5. Jun 14, 2020Phase 2 study in Small Cell Lung CarcinomaNCT04434482 · 59 enrolled · United States, Australia, China and more
  6. Sep 29, 2020Phase 1 study in Solid TumorNCT04584515 · 32 enrolled · China
  7. Oct 12, 2021Phase 1 study in Solid TumorNCT05109832 · 6 enrolled · China
  8. May 20, 20222 phase 1 studies in Solid TumorNCT05391048, NCT05390944
  9. May 23, 2025Phase 1 study in Solid TumorNCT07019194 · 40 enrolled · China
  10. Jun 12, 2025Phase 1 study in Solid TumorNCT07030439 · 32 enrolled · China

TargetBeta

PARP1 →PARP2 →read by rule
“Poly [ADP-ribose] polymerase-1 inhibitor; Poly [ADP-ribose] polymerase 2 inhibitor”ChEMBL 37, by rule

Other programs on the same two targets

ProgramCompanyFurthest phaseStudies
olaparibruleAstraZenecaphase 478
niraparibruleGlaxoSmithKlinephase 443
saruparibruleAstraZenecaphase 314
nesuparibruleJeil Pharmaceuticalphase 24

Studies

All 12 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07030439Solid Tumor · China1CompletedOct 12, 202132
NCT07019194Solid Tumor · China1CompletedJul 15, 202440
NCT05391048Solid Tumor · China1CompletedJul 21, 202236
NCT05390944Solid Tumor · China1CompletedAug 1, 202228
NCT05109832Solid Tumor · China1CompletedDec 6, 20216
NCT04584515Solid Tumor · China1CompletedMar 8, 202132
NCT04434482Small Cell Lung Carcinoma · United States, Australia, China and more2CompletedApr 29, 202459
NCT04351165Solid Tumor · Australia1CompletedFeb 11, 202118
NCT04089189Ovarian Neoplasms · China2CompletedJun 30, 202393
NCT04057729Solid Tumor · China1CompletedSep 27, 201916
NCT03508011Breast Neoplasms · China1CompletedDec 16, 202057
NCT03507543Breast Neoplasms · Australia1CompletedSep 24, 202039

How it is read

Names in the registry

  • “IMP4297”, 5 entries
  • “IMP4297(20mg)”, 2 entries
  • “IMP4297(10mg)”, 2 entries
  • “14C-IMP4297”, 1 entry
  • “Senaparib 10 mg strength capsules manufactured by WuXi STA (Wuxi) Co., Ltd.”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.